1. Home
  2. ZYME vs ARLO Comparison

ZYME vs ARLO Comparison

Compare ZYME & ARLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZYME
  • ARLO
  • Stock Information
  • Founded
  • ZYME 2003
  • ARLO 2018
  • Country
  • ZYME United States
  • ARLO United States
  • Employees
  • ZYME N/A
  • ARLO N/A
  • Industry
  • ZYME Biotechnology: Pharmaceutical Preparations
  • ARLO Consumer Electronics/Appliances
  • Sector
  • ZYME Health Care
  • ARLO Consumer Staples
  • Exchange
  • ZYME Nasdaq
  • ARLO Nasdaq
  • Market Cap
  • ZYME 846.1M
  • ARLO 923.0M
  • IPO Year
  • ZYME 2017
  • ARLO 2018
  • Fundamental
  • Price
  • ZYME $11.31
  • ARLO $12.43
  • Analyst Decision
  • ZYME Buy
  • ARLO Strong Buy
  • Analyst Count
  • ZYME 6
  • ARLO 3
  • Target Price
  • ZYME $19.50
  • ARLO $19.67
  • AVG Volume (30 Days)
  • ZYME 553.2K
  • ARLO 660.9K
  • Earning Date
  • ZYME 05-08-2025
  • ARLO 05-08-2025
  • Dividend Yield
  • ZYME N/A
  • ARLO N/A
  • EPS Growth
  • ZYME N/A
  • ARLO N/A
  • EPS
  • ZYME N/A
  • ARLO N/A
  • Revenue
  • ZYME $93,384,000.00
  • ARLO $505,752,000.00
  • Revenue This Year
  • ZYME $26.29
  • ARLO $4.21
  • Revenue Next Year
  • ZYME $75.78
  • ARLO $7.45
  • P/E Ratio
  • ZYME N/A
  • ARLO N/A
  • Revenue Growth
  • ZYME 85.05
  • ARLO 0.27
  • 52 Week Low
  • ZYME $8.21
  • ARLO $7.84
  • 52 Week High
  • ZYME $17.70
  • ARLO $17.64
  • Technical
  • Relative Strength Index (RSI)
  • ZYME 40.96
  • ARLO 77.82
  • Support Level
  • ZYME $10.86
  • ARLO $10.00
  • Resistance Level
  • ZYME $13.23
  • ARLO $10.53
  • Average True Range (ATR)
  • ZYME 0.56
  • ARLO 0.43
  • MACD
  • ZYME -0.10
  • ARLO 0.28
  • Stochastic Oscillator
  • ZYME 18.78
  • ARLO 98.69

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

About ARLO Arlo Technologies Inc.

Arlo Technologies Inc is engaged in the provision of security and video monitoring solutions for homes and businesses. It combines a cloud infrastructure and mobile app with various smart connected devices to provide users with visibility, insight, and a means to help protect and connect in real-time with the people and things from any location with a Wi-Fi or a cellular connection. The company offers subscription services such as Arlo Secure, Arlo Total Security, and Arlo Safe, and several categories of smart security devices, including smart Wi-Fi and LTE-enabled cameras, video doorbells, floodlight cameras, and home security systems. Geographically, the company generates a majority of its revenue from the United States, followed by Spain, Sweden, and other countries.

Share on Social Networks: